Evolus (EOLS) Net Income towards Common Stockholders (2017 - 2026)

Evolus (EOLS) posted Net Income towards Common Stockholders of -$10.7 million for Q1 2026, down 8310.77% on a QoQ basis from $130000.0 in Q4 2025, and up 43.5% year-over-year from -$7.4 million in Q1 2025.

Evolus (EOLS) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

Evolus' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$10.7 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 43.5% year-over-year to -$10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.4 million (up 22.74% YoY) and the FY2025 annual result came in at -$51.6 million, down 2.42% from the prior year.
  • Net Income towards Common Stockholders was -$10.7 million for Q1 2026 at Evolus, down from $130000.0 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $130000.0 in Q4 2025 and bottomed at -$23.5 million in Q2 2022.
  • A 5-year average of -$14.6 million and a median of -$15.7 million in 2025 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 373.41% — and 2025, when it soared 101.91%.
  • Evolus' Net Income towards Common Stockholders stood at -$13.2 million in 2022, then advanced by 10.13% to -$11.8 million in 2023, then soared by 42.6% to -$6.8 million in 2024, then jumped by 101.91% to $130000.0 in 2025, then plunged by 8310.77% to -$10.7 million in 2026.
  • Business Quant data shows EOLS's Net Income towards Common Stockholders at -$10.7 million in Q1 2026, $130000.0 in Q4 2025, and -$15.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 57.00 Mn
10 Evolus 393.73 Mn 343.94 Mn 48.90 Mn -10.67 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -10.67 Mn
Dec 31, 2025 130,000.00
Sep 30, 2025 -15.74 Mn
Jun 30, 2025 -17.14 Mn
Mar 31, 2025 -18.89 Mn
Dec 31, 2024 -6.79 Mn
Sep 30, 2024 -19.17 Mn
Jun 30, 2024 -11.35 Mn
Mar 31, 2024 -13.11 Mn
Dec 31, 2023 -11.83 Mn
Sep 30, 2023 -16.92 Mn
Jun 30, 2023 -18.14 Mn
Mar 31, 2023 -14.79 Mn
Dec 31, 2022 -13.16 Mn
Sep 30, 2022 -20.28 Mn
Jun 30, 2022 -23.47 Mn
Mar 31, 2022 -17.50 Mn
Dec 31, 2021 -18.18 Mn
Sep 30, 2021 -19.43 Mn
Jun 30, 2021 -15.60 Mn